Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 32 of 51 for:    "Hypogonadism" | "Estrogens"

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01923857
Recruitment Status : Completed
First Posted : August 16, 2013
Last Update Posted : August 11, 2014
Sponsor:
Information provided by (Responsible Party):
Repros Therapeutics Inc.

Brief Summary:
  • To determine and compare the pharmacokinetics (PK) of a single dose of 25 mg Androxal in overweight male subjects with various stages of renal impairment and in volunteers with normal renal function.
  • To compare the safety profile of a single dose of 25 mg Androxal in overweight male subjects with various stages of renal impairment and in volunteers with normal renal function.

Condition or disease Intervention/treatment Phase
Secondary Hypogonadism Drug: Androxal 25 mg Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
Study Start Date : August 2013
Actual Primary Completion Date : August 2014
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Tests

Arm Intervention/treatment
Experimental: Healthy Volunteers
Healthy males age 18-80 with a body mass index(BMI) 25-42 mg/m^2.
Drug: Androxal 25 mg
Other Name: enclomiphene citrate

Experimental: Mild Renal Impairment
Males with mild renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 50-80 mL/min).
Drug: Androxal 25 mg
Other Name: enclomiphene citrate

Experimental: Moderate Renal Impairment
Males with moderate renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 30-50 mL/min).
Drug: Androxal 25 mg
Other Name: enclomiphene citrate

Experimental: Severe renal impairment Drug: Androxal 25 mg
Other Name: enclomiphene citrate




Primary Outcome Measures :
  1. Pharmacokinetic parameters [ Time Frame: 24 hours ]
    Pharmacokinetic parameters calculated as a ratio in subjects with mild or moderate renal impairment to normal after a single dose of 25 mg Androxal.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects with Impaired Renal Function:

Subjects with various stages of impaired renal function must meet all of the following inclusion criteria at screening will be considered for admission to the study:

  1. Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an Institutional Review Board (IRB)-approved form prior to the initiation of any study procedures;
  2. Male, between the ages of 18 and 80 years with Body Mass Index (BMI) between 25 and 42, inclusive, are preferred.
  3. Subjects must meet the criteria of mildly (creatinine clearance 50-80 mL/min) or moderately (creatinine clearance 30-50 mL/min) impaired renal function. The Investigator will assess the renal impairment category of each subject. Substantiation for the diagnosis must be indicated in source documents; (See Appendix B)
  4. Subjects must have evidence of stable renal impairment as determined by the Investigator (See Section 9.3.2, Day -1)
  5. If on medications for treatment of the complications of renal disease, and other concomitant chronic illnesses, subjects must have been taking the medications at a stable dose for at least 10 days prior to the first Androxal dosing date and are then to be continued at the same dose for the duration of the study. The medications must be recorded in source documents;
  6. Subject is willing to remain in the clinic for the screening visit (approximately 1 day for the screening visit) and for the treatment visit (approximately 3 days);
  7. Non-smokers are preferred, but as this is a very restricted population light to moderate smoking will be allowed (no more than 10 cigarettes/day);
  8. Must be able to swallow gelatin capsules;

Subjects with Normal Renal Function:

Healthy volunteers meeting all of the following inclusion criteria at screening will be considered for admission to the study:

  1. Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures;
  2. Male, between the ages of 18 and 60 years with Body Mass Index (BMI) between 25 and 39, inclusive;
  3. Creatinine clearance > 80 mL/min;
  4. Subjects in the control group, generally matched for age and BMI to patients enrolled in the test groups: should be ± 20 years of the mean of mildly and moderately renally impaired subjects included in the study and ± 20% of the average BMI of mildly and moderately renally impaired subjects;
  5. No significant abnormal findings at the screening physical examination as evaluated by the Investigator;
  6. Normal laboratory values or clinically insignificant findings at screening as determined by the Investigator;
  7. Subject is willing to remain in the clinic for the screening visit (approximately 1 day for the first screening visit) and for the treatment visit (approximately 3 days);
  8. No tobacco (nicotine products) use for at least three (3) months prior to the study;
  9. Must be able to swallow gelatin capsules

Exclusion Criteria:

Subjects with Impaired Renal Function

Subjects with various stages of impaired renal function meeting any of the following exclusion criteria at screening will not be enrolled in the study:

  1. Known hypersensitivity to Clomid;
  2. Subjects with clinically significant abnormal liver function as determined by the Investigator;
  3. Subjects who are treated with dialysis;
  4. A physical illness within three (3) months of the study that would interfere with the study as determined by the Investigator;
  5. Participation in a clinical trial with investigational medication within four (4) weeks prior to study medication administration;
  6. A hematocrit >54% or a hemoglobin >17 g/dL. (Sponsor may approve enrollment of subjects with hemoglobin up to 17.5 g/dL if the subject is at a location with high elevation).
  7. An acute illness within five (5) days of study medication administration;
  8. Uncontrolled hypertension based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes will be allowed into the study. Newly diagnosed diabetics need to be treated for at least 48 hours before being enrolled into the study.
  9. Positive urine drug or infectious disease screen at the screening visit based on laboratory testing;
  10. A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude, as determined by the Investigator;
  11. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism);
  12. History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia, or known history of corrected QT interval (QTc) interval prolongation;
  13. The use of prohibited concomitant medications:

    • Drugs that may interfere with cytochrome P450 2D6 (CYP2D6) activity must cease for 7 days prior to first dose of study drug;
  14. An employee or family member of an employee of the study site or the Sponsor.

Subjects with Normal Renal Function:

Healthy volunteers meeting any of the following exclusion criteria at screening will not be enrolled in the study:

  1. Known hypersensitivity to Clomid;
  2. Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant by the Investigator;
  3. Subjects with clinically significant abnormal liver function as determined by the Investigator;
  4. Subject with a significant organ abnormality or disease as determined by the Investigator;
  5. A physical illness within three (3) months of the study that would interfere with the study as determined by the Investigator;
  6. Uncontrolled hypertension based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes will be allowed into the study. Newly diagnosed diabetics need to be treated for at least 48 hours before being enrolled into the study.
  7. A hematocrit >54% or a hemoglobin >17 g/dL. (Sponsor may approve enrollment of subjects with hemoglobin up to 17.5 g/dL if the subject is at a location with high elevation).
  8. Participation in a clinical trial with investigational medication within four (4) weeks prior to study medication administration;
  9. An acute illness within five (5) days of study medication administration;
  10. A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude, as determined by the Investigator;
  11. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism);
  12. History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia, or known history of QTc interval prolongation;
  13. The use of prohibited concomitant medications:

    • Drugs that may interfere with CYP2D6 activity must cease for 7 days prior to first dose of study drug;
  14. An employee or family member of an employee of the study site or the Sponsor.
  15. Positive urine drug or infectious disease screen at the screening visit based on laboratory testing;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01923857


Locations
Layout table for location information
United States, Florida
Miami, Florida, United States, 33014
United States, Minnesota
Minneapolis, Minnesota, United States, 55404
Sponsors and Collaborators
Repros Therapeutics Inc.

Additional Information:
Layout table for additonal information
Responsible Party: Repros Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT01923857     History of Changes
Other Study ID Numbers: ZA-104
First Posted: August 16, 2013    Key Record Dates
Last Update Posted: August 11, 2014
Last Verified: August 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypogonadism
Estrogen Antagonists
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Renal Insufficiency
Gonadal Disorders
Endocrine System Diseases
Kidney Diseases
Urologic Diseases
Enclomiphene
Clomiphene
Zuclomiphene
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents